Lu Si

8.9k total citations · 1 hit paper
302 papers, 4.5k citations indexed

About

Lu Si is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Lu Si has authored 302 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 180 papers in Oncology, 128 papers in Molecular Biology and 60 papers in Immunology. Recurrent topics in Lu Si's work include Cutaneous Melanoma Detection and Management (92 papers), Melanoma and MAPK Pathways (78 papers) and Cancer Immunotherapy and Biomarkers (71 papers). Lu Si is often cited by papers focused on Cutaneous Melanoma Detection and Management (92 papers), Melanoma and MAPK Pathways (78 papers) and Cancer Immunotherapy and Biomarkers (71 papers). Lu Si collaborates with scholars based in China, Ethiopia and United States. Lu Si's co-authors include Jun Guo, Xinan Sheng, Chuanliang Cui, Zhihong Chi, Lili Mao, Yan Kong, Bin Lian, Jie Dai, Bixia Tang and Xieqiao Yan and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Lu Si

276 papers receiving 4.4k citations

Hit Papers

Open-label, Multicenter, Phase II Study of RC48-ADC, a HE... 2020 2026 2022 2024 2020 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
    2020 192 citations Xinan Sheng, Xieqiao Yan et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lu Si China 33 2.7k 2.0k 964 575 487 302 4.5k
Adam I. Riker United States 35 1.6k 0.6× 2.2k 1.1× 1.4k 1.4× 1.0k 1.8× 262 0.5× 100 4.4k
Ester Simeone Italy 33 3.2k 1.2× 1.5k 0.7× 1.6k 1.7× 366 0.6× 689 1.4× 114 4.4k
Klaus Griewank Germany 28 2.5k 0.9× 2.0k 1.0× 1.7k 1.8× 480 0.8× 580 1.2× 82 5.3k
Corrado Caracò Italy 29 2.2k 0.8× 882 0.4× 789 0.8× 357 0.6× 391 0.8× 145 3.2k
Bastian Schilling Germany 36 2.8k 1.1× 1.3k 0.7× 2.1k 2.2× 360 0.6× 493 1.0× 131 4.7k
Peter Mohr Germany 27 2.5k 0.9× 1.9k 0.9× 705 0.7× 223 0.4× 695 1.4× 119 3.7k
Amod A. Sarnaik United States 34 3.0k 1.1× 1.6k 0.8× 1.8k 1.9× 246 0.4× 365 0.7× 129 4.3k
Enzo Médico Italy 41 2.0k 0.7× 3.0k 1.5× 611 0.6× 1.3k 2.2× 626 1.3× 120 6.1k
Takami Sato United States 35 1.7k 0.6× 1.3k 0.6× 1.4k 1.4× 251 0.4× 390 0.8× 179 3.8k
James S. Wilmott Australia 36 4.4k 1.7× 2.8k 1.4× 2.4k 2.5× 798 1.4× 1.0k 2.1× 139 6.4k

Countries citing papers authored by Lu Si

Since Specialization
Citations

This map shows the geographic impact of Lu Si's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lu Si with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lu Si more than expected).

Fields of papers citing papers by Lu Si

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lu Si. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lu Si. The network helps show where Lu Si may publish in the future.

Co-authorship network of co-authors of Lu Si

This figure shows the co-authorship network connecting the top 25 collaborators of Lu Si. A scholar is included among the top collaborators of Lu Si based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lu Si. Lu Si is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Siming, J. B. Wei, Huayan Xu, et al.. (2025). A prognostic model for survival of patients with metastatic upper tract urothelial carcinoma with first-line systemic therapy. World Journal of Urology. 43(1). 206–206.
2.
Zhang, Fenghao, Qian Guo, Zhihong Chi, et al.. (2025). Genomic characterization reveals distinct mutational landscape of acral melanoma in East Asian. Journal of genetics and genomics. 52(4). 525–538. 2 indexed citations
3.
4.
Li, Jingru, Chaozhong Li, Peng Ding, et al.. (2024). Bioinformatics analysis of immune infiltration in human diabetic retinopathy and identification of immune-related hub genes and their ceRNA networks. Scientific Reports. 14(1). 24003–24003. 2 indexed citations
5.
Wen, Yalei, Hui Wang, Xiao Yang, et al.. (2024). Pharmacological targeting of casein kinase 1δ suppresses oncogenic NRAS-driven melanoma. Nature Communications. 15(1). 10088–10088. 3 indexed citations
6.
Li, W., Junjie Gu, Hongwei Fan, et al.. (2024). Evolving cancer resistance to anti-PD-1/PD-L1 antibodies in melanoma: Comprehensive insights with future prospects. Critical Reviews in Oncology/Hematology. 201. 104426–104426. 2 indexed citations
7.
Mao, Lili, Jie Dai, Xue Bai, et al.. (2024). Tucidinostat plus toripalimab in patients with unresectable or metastatic melanoma: An open-label, single-arm phase II study.. Journal of Clinical Oncology. 42(16_suppl). e21527–e21527. 1 indexed citations
8.
Gu, Junjie, Jun Guo, Yu Jiang, et al.. (2024). FCN-159, a MEK1/2 inhibitor, in patients with advanced melanoma harboring NRAS or NF1mutations: A phase 1B dose-expansion study.. Journal of Clinical Oncology. 42(16_suppl). 3095–3095. 1 indexed citations
9.
Tang, Bixia, Rong Duan, Xieqiao Yan, et al.. (2024). Natural history of bone-only metastasis in renal cell carcinoma. Urologic Oncology Seminars and Original Investigations. 42(4). 119.e17–119.e22. 1 indexed citations
10.
Day, Daphne, Vinod Ganju, Ki Y. Chung, et al.. (2023). 1028P Preliminary phase I results from a first-in-human study of EMB-02, a PD-1xLAG-3 bispecific antibody, in patients (pts) with advanced solid tumors. Annals of Oncology. 34. S625–S625. 4 indexed citations
11.
12.
Dong, Yang, Lu Si, Wenming Yang, et al.. (2022). Dual Polarization Modality Fusion Network for Assisting Pathological Diagnosis. IEEE Transactions on Medical Imaging. 42(1). 304–316. 17 indexed citations
13.
Bai, Xue, Michelle Kim, Gyulnara G. Kasumova, et al.. (2021). Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort. Journal for ImmunoTherapy of Cancer. 9(2). e002092–e002092. 8 indexed citations
14.
Bai, Xue, Yan Kong, Zhihong Chi, et al.. (2017). MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases. Clinical Cancer Research. 23(20). 6120–6127. 72 indexed citations
15.
Chang, John Wen‐Cheng, Jun Guo, Chia‐Yen Hung, et al.. (2017). Sunrise in melanoma management: Time to focus on melanoma burden in Asia. Asia-Pacific Journal of Clinical Oncology. 13(6). 423–427. 23 indexed citations
16.
Kong, Yan, Lu Si, Yiqian Li, et al.. (2015). Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors. Clinical Cancer Research. 22(4). 1018–1027. 58 indexed citations
17.
Dai, Jie, Yan Kong, Lu Si, et al.. (2013). Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib. Clinical Cancer Research. 19(24). 6935–6942. 38 indexed citations
18.
Lian, Bin, Lu Si, Chuanliang Cui, et al.. (2013). Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma. Clinical Cancer Research. 19(16). 4488–4498. 121 indexed citations
19.
Si, Lu, Yanyan Zhu, Xiaowei Xu, et al.. (2011). Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma. Clinical Cancer Research. 17(7). 1684–1691. 181 indexed citations
20.
Chi, Zhihong, et al.. (2011). A Clinical Characters and Prognosis Analysis on 357 Cases with Cutaneous Malignant Melanoma in China. Zhongliu fangzhi yanjiu. 38(11). 1316–1319. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Adam I. Riker Breakdown of academic impact, for papers by Ester Simeone Breakdown of academic impact, for papers by Klaus Griewank Breakdown of academic impact, for papers by Corrado Caracò Breakdown of academic impact, for papers by Bastian Schilling Breakdown of academic impact, for papers by Peter Mohr Breakdown of academic impact, for papers by Amod A. Sarnaik Breakdown of academic impact, for papers by Enzo Médico Breakdown of academic impact, for papers by Takami Sato Breakdown of academic impact, for papers by James S. Wilmott
Rankless by CCL
2026